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Cell migrationThe prion protein (PrPC) is predominantly expressed in the nervous and immune systems and is involved in
relevant cell signaling. Microglia participate in neuroimmune interactions, and their regulatory mechanisms
are critical for both health and disease. Despite recent reports with a microglial cell line, little is known about
the relevance of PrPC in brain microglia. We investigated the role of PrPC in mouse primary microglia, and
found no differences between wild type and Prnp-null cells in cell morphology or the expression of a microglial
marker. Translocation of NF-κB to the nucleus also did not differ, nor did cytokine production. The levels of iNOS
were also similar and, ﬁnally, microglia of either genotype showed no differences in either rates of phagocytosis
ormigration, even following activation. Thus, functional roles of PrPC in primarymicroglial cells are— if present—
much more subtle than in transformed microglial cell lines.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The prion protein (PrPC) is a highly conserved glycosyl-
phosphatidylinositol (GPI)-anchored glycoprotein, located at the
surface of the plasma membrane and expressed mainly in the nervous
and immune system (Stahl et al., 1987; Prusiner, 1998). Despite a
known association with neurodegenerative diseases, its physiological
functions are still controversial, although it is believed that PrPC acts
as a scaffold for the assembly of multi-component signaling complexes
at the cell surface (Aguzzi et al., 2008; Linden et al., 2008).
Among the immune cells, PrPC has been implicated in the physiology
of lymphocytes, macrophages, dendritic cells, neutrophils and others
(Isaacs et al., 2006; Mariante et al., 2012), and a role of PrPC was
reported in the activation of microglia (Brown et al., 1998). The latter
are mononuclear phagocytes resident in the brain parenchyma, and
constitute about 5 to 20% of the total number of glial cells, depending
on the speciﬁc region of the brain (Lawson et al., 1990; Perry and
Gordon, 1991). They constitute the main representative of the immune
system in the central nervous system, and participate in both neuronal
homeostasis and in inﬂammation (Saijo and Glass, 2011).Iba-1, ionized calcium binding
oxide synthase; LPS, lipopoly-
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ante).Microglia are activated in the context of numerous injuries or
diseases that affect theCNS, both in human and in corresponding animal
models (Perry et al., 2010). However, the functions of these cells in
neurodegenerative diseases are not entirely understood. Microglia can
have either a protective role, by removing protein aggregates in trans-
missible spongiform encephalopathies (Brown and Kretzschmar,
1997; Rezaie and Lantos, 2001) and Aβ aggregates in Alzheimer
disease (Lee and Landreth, 2010; Sokolowski and Mandell, 2011), or a
pathogenic role, through exacerbation of inﬂammation with the
production of cytokines, inﬂammatory mediators and other neuro-
toxins that may contribute to neuronal dysfunction and damage
(Perry et al., 2010; Saijo and Glass, 2011). Thus, it is expected that
the activation of microglia is tightly regulated, and investigation
of its control mechanisms should contribute to better understanding
of both the modulation of its phenotypes and its roles in
pathophysiology.
Microglial PrPC has received little attention following the early
evidence for its role in cellular activation (Brown et al., 1998), and
only recently a series of studies of the microglial cell line BV-2 revived
this issue. Thus, an increase in the transcription of the PrPC-coding
Prnp gene was reported following stimuli such as treatment with the
neurotoxic prion peptide PrP106–126 (Bai et al., 2010) or infection with
Mycobacterium bovis (Ding et al., 2013). Further, the silencing of PrPC
with siRNA indicated that PrPC affects the response of BV-2 cells to
bacterial infection (Ding et al., 2013) and modulates the change of
those cells' phenotype from a quiescent to an activated state (Shi
et al., 2013).
Fig. 1. Primary microglia cells isolated from cultures of cells obtained from brain of wild
type (WT) or Prnp-null (KO) mice, and spontaneously adhered to glass coverslips.
Bar = 40 μm.
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both the activation and cell responses of this microglial cell line, the
relationship between PrPC and the physiology of microglia in vivo or
ex vivo is unclear. Here, we examined the functional properties of
primary cultures of microglia obtained from both wild type and Prnp-
null mouse brains. The results showed no evidence of participation of
PrPC in microglial activation and functions.
2. Materials and methods
2.1. Reagents
DMEM-F12 culture medium was from Gibco. Fetal bovine serum
was from Cultilab. LPS (Salmonella enterica) and FITC-labeled zymosan
(Saccharomyces cerevisiae)were fromSigma and Invitrogen, respectively.
Monoclonal anti-NF-κB p65 (20/NF-κB/p65) and anti-PrPC (SAF83) anti-
bodies were from BD Biosciences and Cayman Chemical, respectively.
Polyclonal anti-Iba-1 and anti-iNOSwere fromWako andAbcam, respec-
tively, and anti-Erk2was from Santa Cruz Biotechnology. Secondary anti-
bodies for immunoﬂuorescence (Alexa Fluor 488 and Alexa Fluor 555)
and western blots (anti-mouse IgG-HRP) were from Life Technologies
and Cell Signaling, respectively. ELISA kits for cytokine assays were
from eBioscience.
2.2. Mouse strains and genotyping
Prion protein knockout mice originally produced in 129/Ola back-
ground (Manson et al., 1994), and serially backcrossed into the C57BL/
10SnJ strain (Tribouillard-Tanvier et al., 2009), were kindly provided
by Bruce Chesebro and Richard Race (Rocky Mountain Laboratories,
National Institute of Allergy and Infectious Diseases, USA). Descendants
of heterozygous littermatesweremaintained by serial backcrossing into
C57BL/10SnJ, and used to derive wild type and Prnp-null mice, here
referred to as B10.129Ola. Animals were housed in plastic boxes with
food and water ad libitum, and were maintained in a 12 h light/dark
cycle. Experiments were done with newborn mice (0 to 2 postnatal
days) in accordance with current guidelines for the care and use of
laboratory animals, as described by the National Institutes of Health
and approved by the Committee for the Use of Experimental Animals
from the Center of Health Sciences, Federal University of Rio de Janeiro.
All mice used in the present study were genotyped by PCR as
described elsewhere (Steele et al., 2006). Brieﬂy, DNA from tails was
ampliﬁed in a multiplex reaction using the primer pairs 5′-TCATCCCA
CGATCAGGAAGATGAG-3′ and 5′-ATGGCGAACCTTGGCTACTGGCTG-3′,
which anneal to the start and stop codons of the Prnp gene open reading
frame and generate a fragment of 750 bp, and 5′-TTGAGCCTGGCGAACA
GTTC-3′ and 5′-GATGGATTGCACGCAGGTTC-3′, which anneal to the
neomycin resistance gene present in Prnp-null mice and generate a
product of 550 bp. Cycling conditions were 94 °C for 3 min, 30 cycles
at 94 °C for 30 s, 62 °C for 30 s, and 72 °C for 1 min, followed by a ﬁnal
extension at 72 °C for 10 min. PrPC content from microglial cell lysates
was further veriﬁed by western blots (Supplemental methods and
Supplemental Fig. 1).
2.3. Primary cultures of microglial cells
Microglial cells were obtained from the brains of newborn mice as
described previously (Théry et al., 1991; Fonseca et al., 2012). Brieﬂy,
mice were decapitated, their brains were dissected and the meninges
were carefully stripped off. Tissues were mechanically dissociated and
resuspended in DMEM-F12 medium supplemented with L-glutamine,
1% penicillin/streptomycin, and 10% fetal bovine serum. Dissociated
cells were plated in poly-L-ornithine-coated ﬂasks and incubated at
37 °C for 14 days in a humidiﬁed chamber with 5% CO2. Floating
microglial cells were collected from culture supernatants, counted,
plated as described in the following sections and either stimulated ornotwith 1 μg/ml LPS for 24–72h. Four to sixmice pups of each genotype
were used for each culture.Microglial cultures presented N97% purity as
veriﬁed by Iba-1 expression.
2.4. Immunocytochemistry
Microglial cells plated in a 24-well plate containing round coverslips
(7 × 104 cells per well) were either treated or not with LPS for 24 h,
ﬁxed with 4% paraformaldehyde in phosphate buffer 0.1 M (pH 7.4),
permeabilized with 0.5% Triton X-100 and blocked with 3% bovine
serum albumin. The coverslips were incubated overnight at 4 °Cwith pri-
mary antibodies anti-Iba-1 (1:200), anti-NF-κB (1:50) or anti-iNOS
(1:300), followed by a secondary antibody (Alexa Fluor 488 or 555,
1:300) for 90 min at room temperature. Cell nuclei were stained with
DAPI (1 μg/ml). The coverslips were mounted and observed in Zeiss
Axio Imager.M2 ﬂuorescence microscope equipped with an ApoTome
module. The number of iNOS-positive cells was calculated from images
acquired with the AxioVision mosaic tool, which generated images
consisting of 225 photos (15 × 15 matrix) covering virtually the entire
area of each coverslip. At least 12,000 cells of each group were counted
and analyzed in each experiment. The ﬂuorescence intensity of iNOS
staining was estimated as described elsewhere (Gavet and Pines, 2010)
and normalized to the ﬂuorescence of WT untreated microglial cells.
We measured the individual ﬂuorescence of at least 300 cells of each
group. Image analysis, processing and quantiﬁcation were done with
AxioVision 4.8, Adobe Photoshop CS5 and ImageJ 1.48v softwares.
2.5. Cytokine measurements
The release of cytokines was estimated from cells seeded in 24-well
plates (5× 105 cells perwell), and either treated or notwith LPS for 24 h
as described above. Supernatantswere collected, centrifuged at 10,000 g
for 5 min, and the levels of IL-1β, IL-6, TNF-α, IL-10 and IL-4 were
measured by ELISA according to the manufacturer's instructions.
2.6. Phagocytosis assay
Microglial cells were plated (7 × 104 cells per well) and either
treated or not with LPS as described above. Zymosan-FITC bioparticles
were opsonized with 30% normal mouse serum in DMEM-F12 for 1 h
at 37 °C, and added to cell cultures 90 min prior to the end of LPS
treatment at a ratio of 10:1 (zymosan:microglial cell). Afterwards,
cells were washed three times with cold phosphate buffered saline to
remove non-phagocytized particles, ﬁxed with 4% paraformaldehyde
and labeled with anti-Iba-1 (1:200) and DAPI as described before. The
slides were examined and photographed in a Zeiss Axio Imager.M2
ﬂuorescence microscope. For quantiﬁcation, cells containing three or
Fig. 2. Expression of the microglial marker Iba-1 by primary microglia obtained from
either wild type (WT) or Prnp-null (KO) mice. Cells were stained with a polyclonal anti-
Iba-1 antibody (red), and their nuclei were counterstainedwith DAPI (blue). Bar= 20 μm.
Fig. 4. Cytokine production by either wild type (WT) or Prnp-null (KO) microglia in
response to LPS treatment. Conditioned media was analyzed for the presence of
(a) TNF-α, (b) IL-1β, (c) IL-6 or (d) IL-10 by ELISA; *p b 0.05, **p b 0.01 and ***p b 0.001
comparing treated (LPS) to untreated (CTR) groups; n = 3.
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Almeida et al., 2005). The number of phagocytic cells was calculated
from 100 photos (10 × 10 matrix) of each coverslip. At least 12,000
cells of each group were counted and analyzed.
2.7. Scratch wound migration assay
Microglial cells (7× 104 cells perwell)were seeded in 96-well plates
and incubated overnight in a humidiﬁed chamber at 37 °C with 5% CO2.
Twenty-four hours after plating cells, a scratchwas gently performed in
each of the wells with a sterile 200 μl micropipette tip, followed by two
washes with medium to remove ﬂoating cells. Afterwards, cells were
treated with LPS and immediately photographed in a Zeiss Axiovert 35
microscope (0 h time point). Cells were incubated for a further 48 or
72 h to allow time for migration into the cell-free area, ﬁxed with para-
formaldehyde and stained with DAPI. Photos were taken of the sameFig. 3. Translocation of NF-κB to the nucleus of microglia cells either subject (LPS) or not (CTR)
and their nuclei were counterstained with DAPI (blue). Bar = 20 μm.region of the scratch. Quantiﬁcation of cell migration was done using
ImageJ, by counting the total number of cells in theﬁeld and the number
of cells present in the slit.2.8. Statistical analysis
Results are expressed asmeans±S.E.M., and the datawere analyzed
by two-way analysis of variance with Bonferroni post tests using
GraphPad Prism5.01 software. A p value of b0.05was considered signif-
icant. The number of experiments is indicated in the ﬁgure legends.to LPS treatment. Cells were stained with a monoclonal anti-NF-κB p65 antibody (green),
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3.1. Absence of PrPC does not affect microglia morphology, adhesion or
content of a microglial marker
We ﬁrst examined the general morphology and the adhesion of
microglia in primary cultures obtained from either wild type (WT) or
Prnp-null (KO) mice. No difference was found between cells of distinct
genotypes (Fig. 1). Next, we tested for the expression of Iba-1, a speciﬁc
macrophage/microglia marker (Kanazawa et al., 2002). Iba-1 staining
was observed in over 97% of cells of both wild type and Prnp-null geno-
types, and the pattern of expression and the amount of staining were
similar in cells either expressing or not the prion protein (Fig. 2).3.2. Translocation of NF-κB and production of cytokines in response to LPS
are not affected by the lack of PrPC
We next asked whether the lack of the prion protein would affect
cell activation and cytokine production in response to bacterial
lipopolysaccharide, a well-known microglial activator. NF-κB is an
important upstream modulator of cytokine expression in microglia
(Pahl, 1999), and its translocation to the nucleus in response to infection
is a marker of cellular activation (O'Neill and Kaltschmidt, 1997). As
expected, LPS induced massive translocation to the nucleus of NF-κB
(Fig. 3). However, no differences in either NF-κB content or localization
were observed when comparing wild type and Prnp-null microglia.Fig. 5. Expression of iNOS by either wild type (WT) or Prnp-null (KO)microglia stimulated with
were counterstained with DAPI (blue). (b) Quantiﬁcation of iNOS+ cells of each genotype befor
genotype before or after LPS treatment. ***p b 0.001 and **p b 0.01 comparing treated (LPS) toAccordingly, LPS induced a substantial inﬂammatory response, with
the production by stimulated microglia of TNF-α, IL-1β and IL-6
(Fig. 4a–c). Yet, the levels of inﬂammatory markers were similar in
both wild type and Prnp-null microglia.
We next examined the production of regulatory cytokines, which
help to control the inﬂammatory process and avoid its exacerbation
and consequent tissue damage. LPS treatment induced the production
of IL-10 again independent of PrPC (Fig. 4d), whereas IL-4 levels were
below the detection limit in the supernatants of microglia cultures of
both genotypes (data not shown).3.3. Upregulation of iNOS in response to LPS is not affected by the lack
of PrPC
Inﬂammatory mediators other than cytokines have multiple effects
upon the inﬂammatory process, such as nitric oxide. The inducible nitric
oxide synthase is a key enzyme in the production of NO following
inﬂammatory stimulation, and thus it has an important role in the
regulation of the immune responses, as its product affects virtually
every step of the progression of inﬂammation (Guzik et al., 2003).
We therefore tested whether the regulation of iNOS content in
response to inﬂammation was dependent on the genotype of the
microglia. To this end, we stimulated the cells with LPS and quantiﬁed
the number of cells expressing the inducible NO synthase (Borghan
et al., 2007). Treatment with LPS induced increased number of iNOS
expressing cells and ﬂuorescence intensity, but the quantity of iNOS-LPS. (a) Cells were stained with a polyclonal anti-iNOS antibody (green), and their nuclei
e or after LPS treatment. (c) iNOS normalized ﬂuorescence intensity of iNOS+ cells of each
untreated (CTR) groups; n = 3. Bars = 40 μm.
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cells from both genotypes (Fig. 5).
3.4. Neither phagocytosis nor migratory capacity are affected by the lack of
PrPC
The relevance of the prion protein formicroglial physiologywas also
addressed in functional assays. We had previously found evidence of
hyperphagocytosis by peritoneal macrophages and bystander retinal
glial cells in Prnp-null mice as compared with wild type (de Almeida
et al., 2005). Phagocytic activity of microglia was therefore addressed
in an assay of uptake of zymosan-FITC bioparticles. Surprisingly,
although the basal phagocytic activity of microglial cells was high — as
expected for young primary microglial cultures (Caldeira et al.,
2014) — there was no sign of an effect of the microglia genotype in
the uptake of zymosan before or after LPS treatment (Fig. 6). Migratory
capacity ofmicroglial cells was investigated in a scratch assay. LPS treat-
ment signiﬁcantly increased migratory capacity of cells toward the
scratch, but again no difference was found between genotypes (Fig. 7).
4. Discussion
In the present study we found that primary Prnp-null microglia
behave similarly to wild type cells in a variety of functional properties
both in basal conditions, as well as in response to LPS. There were no
differences between genotypes in (i) morphology; (ii) expression ofFig. 6. Phagocytosis of zymosan particles by either wild type (WT) or Prnp-null (KO) microglia s
LPS and exposed to FITC-conjugated zymosan particles at a ratio of 10:1 (zymosan:microglial ce
counterstained with DAPI (blue). (b) Magniﬁcation of the regions highlighted in a. (c) Quantiﬁ
particles; n = 3. Bars = 40 μm (a) or 20 μm (b).the microglial marker Iba-1; (iii) translocation of NF-κB to the nucleus;
(iv) production of several cytokines; (v) levels of inducible NO
synthase; (vi) migration nor (vii) phagocytosis following activation.
Our results differ greatly from recent reports that PrPC contributes
signiﬁcantly to both the activation (Shi et al., 2013) and inﬂammatory
response (Ding et al., 2013) of the BV-2 microglial cell line. In those
studies, downregulation of Prnp with siRNA prior to M. bovis infection
reduced bacteria-induced upregulation of IL-1β, TNF-α and iNOS, but
not of IL-10 and TGF-β, consistent with a role for PrPC in the response
of BV-2 cells to infection (Ding et al., 2013). Silencing of Prnp also
affected the responsiveness of BV-2 cells to interferon-γ or IL-4, but not
to IL-10, thus suggesting a role of PrPC in the modulation of microglia
phenotype from quiescence to an activated state (Shi et al., 2013).
The remarkable differences in the behavior of brain-derivedmicrog-
lia as compared to the BV-2 cell line are in linewith similar comparisons
between primary cells and corresponding cell lines from various tissues
(Wilkening et al., 2003; LePage et al., 2005; Alge et al., 2006;Myers et al.,
2008; Chamberlain et al., 2009; Cree et al., 2010; Kraus et al., 2010).
From our results, it is likely that major functional properties of brain
microglia are relatively insensitive to the lack of the prion protein. How-
ever, a number of additional characteristics remain to be tested, such as,
for example, the kinetics of nucleo-cytoplasmic shuttling of NF-κB.
Particular among the properties we now examined in primary
microglia was the rate of phagocytosis. Our original ﬁndings (de
Almeida et al., 2005) of hyperphagocytosis in peritoneal macrophages
of Prnp-null mice of a mixed C57BL/6J-129/Sv genetic backgroundubmitted (LPS) or not (CTR) to LPS treatment. Cells plated in coverslips were treatedwith
ll). Afterwards, cells were stainedwith a polyclonal anti-Iba-1 antibody (red). Nuclei were
cation of phagocytic cells of each genotype containing at least three internalized zymosan
Fig. 7.Migration of either wild type (WT) or Prnp-null (KO)microglia in response to LPS treatment. Plated cells separated by surface scratchwere treated with LPS and stained with DAPI.
(b) Migrated cells were quantiﬁed at 48 and 72 h after treatment by counting the total number of cells in the ﬁeld and the number of cells present in the slit (highlighted region in a).
**p b 0.01 comparing treated (LPS) to untreated (CTR) groups; n = 3. Bar = 100 μm.
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in a recent study by other authors (Nuvolone et al., 2013). Nonetheless,
the extensive genetic analysis made by the Aguzzi group showed that
the effect we had attributed to PrPC (de Almeida et al., 2005) was
actually traceable to the signal regulatory protein α (Sirpa) gene,
that signiﬁcantly impacts phagocytosis by peritoneal macrophages
(Matozaki et al., 2009). A polymorphism of Sirpa is present in the
129S7/SvEvBrd genotype of the original embryonic stem cells that
originated the B6.129Sv mice (Büeler et al., 1992), and the Sirpa gene
is closely linked to Prnp. Indeed, Sirpa was shown to co-segregate with
the targeted Prnp locus for up to 17 generations in several 129Sv-
derived hybrid mouse lines (Nuvolone et al., 2013).
The 129/Ola mouse sub-strain carries the same polymorphism of
Sirpa as found in 129/Sv, and 129/Ola co-isogenic mice did not show
differing phagocytosis between Prnp-null and wild type cells (Nuvolone
et al., 2013). In our original study (de Almeida et al., 2005), we had
reported hyperphagocytosis of peritoneal macrophages from the
B10.129Ola strain used in the current study, as compared with wild
type C57BL/10SnJ, but wild type B10.129Ola macrophages were not
examined. The CD47-Sirpa signaling system, however, also regulates
properties of polymorphonuclear cells, such as adhesion, migration
and phagocytosis, as well as macrophage-mediated clearance of
apoptotic neutrophils, with robust functional consequences (Parkos
et al., 1996; Liu et al., 2001; Lawrence et al., 2009; Lee et al., 2010;
Myers et al., 2011; Zen et al., 2013; Stenberg et al., 2013, 2014;
Greenlee-Wacker et al., 2014). Interestingly, we have found no
difference between Prnp-null and wild type neutrophils taken from
B10.129Ola mice in their sensitivity to spontaneous or peroxide-
induced apoptosis in vitro (Mariante et al., 2012), nor in their recruit-
ment to the peritoneal cavity following in vivo injections of zymosan
(R.M. Mariante et al., unpublished results).Taken together, the results with both neutrophils and microglia
suggest that the mixed B10.129Ola sub-strain in our colony may have
lost the differential effect of the Sirpa polymorphism derived from the
129Ola background (Nuvolone et al., 2013). This could be due to segre-
gation by chance of Sirpa after long-term backcrossing of B10.129Ola
heterozygous mice into the C57BL/10SnJ strain. Alternatively, the latter
strain may carry other genetic determinants that affect Sirpa-regulated
functions, either alone or through epistasis, whereas such determinants
are either absent or irrelevant for immune responses in the B6.129Sv
mixed strain. The C57BL/6J and C57BL/10SnJ mice have been separately
inbred since 1947 (JAX notes — http://jaxmice.jax.org/strain/000665.
html), and expression of certain genes, single nucleotide polymor-
phisms, as well as functional properties of a variety of organs and
systems have, indeed, been shown to differ between mice of either
strain (Steward et al., 1999; Shuttleworth and Connor, 2001; Turk
et al., 2004; Deacon et al., 2007; Xia et al., 2010; Wiltshire et al., 2011;
Roche et al., 2012; Damerla et al., 2014). Undoubtedly, the interplay of
both Prnp and Sirpa genes and their products deserves further attention,
to unravel both their genetic and functional interactions, which may
affect not only immune cells but functional properties attributed to
PrPC in other organs and systems. However, such an investigation is
beyond the scope of the current study.
5. Conclusions
An extensive examination of various functional properties indicated
that the lack of the prion protein has little effect upon the behavior of
microglia, contrary to the distinctive properties of the BV-2 microglial
cell line in the presence or the absence of PrPC. Given the growing
interest in unraveling the functions of the prion protein in both health
and disease, our data warrant a cautionary approach to the testing of
31L.P. Pinheiro et al. / Journal of Neuroimmunology 286 (2015) 25–32PrPC roles in cell lines without simultaneous veriﬁcation in primary
cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2015.07.002.
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